KYNB
$7.37
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.
Intraday
Recent News
Kyntra Bio Inc (KYNB) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline with ...
Kyntra Bio Inc (KYNB) faces revenue challenges but extends cash runway and advances clinical trials to bolster future growth.
Kyntra Bio (KYNB) Q4 2025 Earnings Call Transcript
Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in Kyntra Bio, Inc.'s filings with the SEC, including our most recent Form 10-K and Form 10-Q. Kyntra Bio, Inc. does not undertake any obligation to update publicly any forward-looking statements whether as a result of new information, future events, or otherwise.
Kyntra Bio: Q4 Earnings Snapshot
SAN FRANCISCO (AP) — Kyntra Bio, Inc. KYNB) on Monday reported a loss of $14.2 million in its fourth quarter. The San Francisco-based company said it had a loss of $3.51 per share.
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Monte Rosa Therapeutics (GLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates
Septerna, Inc. (SEPN) delivered earnings and revenue surprises of -5.50% and +17.98%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?